On a dusty street in Soweto, a small spaza shop sells loose tablets from a plastic bag for a few rand each. No pharmacist, no prescription, no package insert. The pills are imported fluoroquinolones—ciprofloxacin, norfloxacin—manufactured in India and China, brought in through informal trade channels. For women with recurrent urinary tract infections, these corner shops offer a quick fix. But the fix is backfiring. Resistance to these once-reliable antibiotics is climbing steeply, and the consequences are showing up in public hospital wards where patients now require intravenous last-resort drugs.

Loose Antibiotics Sold Over the Counter Fuel a Resistant UTI Crisis

In Johannesburg’s townships, spaza shops routinely sell antibiotics without a prescription, despite a 1965 law that requires a pharmacist's oversight. A 2024 survey by the University of the Witwatersrand found that more than 60% of informal vendors in Soweto stocked at least one antibiotic, and nearly all sold it loose—no labeling, no dosage instructions. Customers typically buy a few tablets at a time, often enough to relieve symptoms but not to complete a full course.

This practice is driving resistance. In Gauteng province, resistance to ciprofloxacin among urinary E. coli isolates now exceeds 50% in some community-based surveillance samples, according to data presented at the 2025 South African Society for Microbiology conference. That is roughly double the rate seen a decade ago. The World Health Organization has flagged this pattern as reminiscent of early carbapenem-resistance outbreaks, warning that informal antibiotic markets could accelerate the spread of multidrug-resistant organisms.

The problem is not unique to South Africa, but the scale here is striking. A 2023 study in the South African Medical Journal estimated that up to 40% of antibiotics consumed in the country are obtained without a prescription, the majority from informal vendors. Fluoroquinolones are among the most commonly sold, because they are cheap, broad-spectrum, and widely available on the black market.

Regulatory efforts have been uneven. The South African Health Products Regulatory Authority has conducted raids, but enforcement is sporadic. Vendors often receive warnings rather than fines, and the supply chain is difficult to trace. As one official told a local newspaper, "We are fighting a hydra—cut off one head, two more appear."

How a Common Infection Evolves into a Treatment-Resistant Threat

Urinary tract infections are among the most common bacterial infections worldwide, and women bear the brunt: roughly half experience at least one in their lifetime. Most are caused by Escherichia coli, a bacterium that normally lives harmlessly in the gut. When it migrates to the urinary tract, it triggers inflammation and pain. Uncomplicated UTIs are usually treated with a short course of oral antibiotics, often a fluoroquinolone like ciprofloxacin.

But repeated exposure to antibiotics, especially at sub-therapeutic doses, selects for resistant strains. Each time a patient takes a partial course—say, two tablets instead of seven—the most susceptible bacteria die, while those with mutations that confer resistance survive and multiply. Over time, the population shifts toward resistance. This is exactly what is happening in South African communities where loose antibiotics are common.

Resistance to fluoroquinolones is particularly concerning because these drugs are also used for other infections, including typhoid fever and prostatitis. When first-line oral agents fail, clinicians must turn to alternatives like nitrofurantoin or fosfomycin, which are more expensive and less widely available. In some public hospitals, patients with resistant UTIs now receive intravenous ertapenem, a carbapenem reserved for multidrug-resistant infections.

The burden falls disproportionately on women, who already face higher rates of UTI recurrence. A 2025 study from Chris Hani Baragwanath Hospital in Soweto found that women with resistant UTIs were twice as likely to be hospitalized as those with susceptible infections. Many had used antibiotics purchased from informal vendors in the preceding year. The study's lead author, Dr. Nomsa Mkhize, noted, "We are seeing a generation of young women who have lost access to simple, effective treatment for a condition that should be easily managed."

Regulatory Gaps Allow Imported Antibiotics to Bypass Quality Checks

The antibiotics sold in spaza shops are not subject to the same quality controls as those dispensed in pharmacies. Many are imported from manufacturers in India and China, where production standards vary. Samples tested by the South African National Accreditation System have found sub-potent active ingredients—some tablets contained as little as 60% of the labeled dose. Others failed disintegration tests, meaning they may not dissolve properly in the body.

There is also no cold chain or expiry-date tracking. Loose pills may have been stored in hot warehouses or transported in unventilated trucks, degrading the active compound. A 2024 investigation by the Mail & Guardian found that some spaza shop antibiotics had expired more than a year earlier. Vendors rarely check dates, and customers have no way to verify what they are buying.

The informal market undermines South Africa's national antimicrobial stewardship program, which aims to reduce inappropriate antibiotic use. The program relies on prescription-only enforcement, but that enforcement is weak in areas where pharmacies are scarce and spaza shops are ubiquitous. In many townships, a spaza shop is closer than a clinic, and it does not require a consultation fee or a long wait.

Parallel markets also make it difficult to track consumption. South Africa has no system for monitoring antibiotic sales outside registered pharmacies, so resistance surveillance relies on clinical isolates, which capture only a fraction of the true burden. Researchers at the University of Cape Town have called for a national registry of antibiotic imports, including those destined for informal trade, but the proposal has not gained political traction.

Patient Stories from Soweto Show the Human Cost of Resistance

Thandi, a 34-year-old teacher from Soweto, first developed a urinary tract infection in 2022. She bought ciprofloxacin from a corner shop near her home, took a few tablets until the burning stopped, and felt better. The infection returned three months later. She repeated the pattern. By the fifth episode, the ciprofloxacin no longer worked. "I took the whole packet, but nothing happened," she recalls. "The pain got worse."

Thandi eventually visited a public clinic, where a urine culture showed that her E. coli was resistant to ciprofloxacin, norfloxacin, and ofloxacin. She was treated with a seven-day course of nitrofurantoin, which cost her more than the loose antibiotics. But the infection recurred again. In early 2025, she required intravenous ertapenem at a public hospital. "I never knew antibiotics could stop working," she says. "I thought they always worked."

Another patient, a 28-year-old cashier named Zanele, spent her savings on a black-market cephalosporin injection after oral antibiotics failed. She bought the injection from a man who sold medicines out of a suitcase at a taxi rank. The injection caused a severe allergic reaction, and she ended up in an emergency room. "I was desperate," she says. "I just wanted the pain to stop."

Both women say they had no idea that taking incomplete courses could breed resistance. Public health campaigns have not reached them. When asked whether they would have completed a full course if they could afford it, both said yes. The issue is not just awareness—it is access and cost. A full course of ciprofloxacin from a pharmacy costs roughly 50 rand, while loose tablets from a spaza shop cost 5 rand for three. For many, the cheaper option is the only option.

Community-Based Surveillance Reveals Resistance Hotspots

Researchers at the University of the Witwatersrand have been mapping resistance in Gauteng townships by testing urine samples from clinic patients and correlating results with proximity to informal drug sellers. Their preliminary data, published in The Lancet Global Health in 2025, show that resistance to norfloxacin and ofloxacin clusters near areas with high densities of spaza shops selling antibiotics. The odds of a resistant infection were roughly 2.5 times higher for patients living within 500 meters of an informal vendor.

Genetic analysis of the resistant E. coli isolates revealed that many carry the same resistance genes—qnrS and aac(6')-Ib-cr—found in environmental samples collected from streams near markets. Wastewater sampling confirmed the presence of antibiotic residues, including ciprofloxacin and norfloxacin, in water bodies adjacent to informal trading areas. This suggests that the antibiotics are not only consumed but also excreted, entering the environment and further selecting for resistance in bacteria.

The mapping approach could guide targeted regulatory sweeps. If enforcement agencies know which neighborhoods have the highest density of antibiotic-selling spaza shops, they can prioritize inspections and fines. But the researchers caution that enforcement alone is insufficient. "We need to address the demand side," says Dr. Sipho Dlamini, a co-author of the study. "People buy from spaza shops because they cannot afford or access proper care."

Community-based surveillance also highlights the role of social networks. In focus groups, women reported sharing antibiotics with neighbors and family members who had similar symptoms. Some said they kept leftover tablets from previous infections. This practice, known as "antibiotic sharing," is common in settings where healthcare is expensive or inconvenient. It amplifies the selection pressure for resistance, because the dose and duration are almost never appropriate.

What Clinicians and Policymakers Can Do Now

There is no single solution, but several interventions could slow the rise of resistant UTIs. The most immediate is to improve access to rapid diagnostic tests at the primary care level. Simple dipstick tests that detect nitrite and leukocyte esterase can confirm a UTI in minutes, allowing clinicians to prescribe the right antibiotic without waiting for a culture. These tests cost roughly 5 rand each and are already available in some public clinics, but stockouts are common.

Another priority is to enforce the prescription-only law more consistently. Spot fines for informal sellers, combined with public awareness campaigns, could reduce supply. But enforcement must be accompanied by efforts to expand access to formal healthcare. Mobile clinics, extended pharmacy hours, and subsidized consultations could pull patients away from spaza shops. In Brazil, a similar program reduced informal antibiotic sales by roughly 30% within two years.

Subsidizing first-line alternatives like nitrofurantoin and fosfomycin could also reduce demand for fluoroquinolones. These drugs are less prone to resistance and are already recommended by South African treatment guidelines, but they are more expensive and less widely stocked. A government subsidy could make them cheaper than loose ciprofloxacin, shifting consumer behavior.

Finally, integrating antibiotic sales data from informal markets into national resistance surveillance would provide a more complete picture. Currently, surveillance relies on clinical isolates, which capture only infections severe enough to prompt a clinic visit. Community-based sampling, like the Wits University project, could be scaled up with modest funding. The WHO has endorsed such approaches as part of its Global Antimicrobial Resistance Surveillance System.

Trade-offs and Counter-arguments: The Limits of Enforcement and the Role of Market Forces

Critics of stricter enforcement argue that simply cracking down on spaza shops may drive the trade further underground, making it harder to monitor and potentially more dangerous. In some cases, patients who lose access to loose antibiotics may turn to even less regulated sources, such as street vendors selling counterfeit or adulterated products. A 2023 analysis by the South African Pharmacy Council noted that a complete ban on informal sales, without alternative access, could paradoxically increase harm by pushing patients toward unidentifiable injections or herbal remedies with unknown toxicity.

Others point out that the informal market fills a genuine gap in the healthcare system. In many townships, public clinics have limited hours, long queues, and frequent stockouts of first-line antibiotics. A patient with a painful UTI may wait hours for a consultation, only to be told the clinic has no nitrofurantoin and to come back another day. The spaza shop, open seven days a week until late, offers immediate relief. Eliminating that option without fixing the underlying access problems would be ethically questionable.

Moreover, some economists argue that price signals and consumer education could be more effective than prohibition. If first-line antibiotics like nitrofurantoin were made cheaper and more widely available through formal channels, demand for fluoroquinolones from spaza shops might naturally decline. A pilot program in the Western Cape, where mobile clinics dispensed free nitrofurantoin to women with UTI symptoms, saw a measurable drop in self-reported use of informal antibiotics over a six-month period. Scaling such programs nationally would require investment but could yield long-term savings by reducing resistance-related hospitalizations.

There is also a cultural dimension. In some communities, antibiotics are viewed as a commodity to be bought and sold like any other medicine, and the idea of needing a prescription for a simple infection seems bureaucratic and expensive. Public health campaigns that frame antibiotic resistance as a community threat, rather than an individual problem, may resonate more strongly. For example, in KwaZulu-Natal, a radio drama series that followed the story of a fictional family dealing with a resistant infection led to a measurable increase in knowledge about completing courses and avoiding sharing medicines. Such approaches take time, but they address the root of the problem: the perception that antibiotics are harmless and always effective.

Antibiotic Resistance in a Broader Context: Lessons from Other Regions

South Africa is not alone in grappling with informal antibiotic markets. Similar patterns have been documented in Nigeria, where open markets sell loose antibiotics alongside food and clothing; in Indonesia, where village kiosks stock amoxicillin and ciprofloxacin without oversight; and in parts of Latin America, where pharmacies themselves sometimes dispense antibiotics without prescriptions. In each setting, the consequences are similar: rising resistance, treatment failures, and increased reliance on last-resort drugs.

What distinguishes South Africa is the relative strength of its formal healthcare system and the presence of active research groups documenting the problem. The country has a well-developed network of public hospitals, a national antimicrobial stewardship program, and a regulatory authority with the legal power to act. The challenge is not a lack of knowledge or tools, but a gap between policy and implementation. Closing that gap will require political will, sustained funding, and a willingness to experiment with interventions that address both supply and demand.

Internationally, the WHO has called for a "One Health" approach to antimicrobial resistance, recognizing that human health, animal health, and the environment are interconnected. In South Africa, this means not only regulating human antibiotic use but also addressing veterinary use and agricultural runoff, which contribute to environmental resistance reservoirs. A 2025 study from the University of Pretoria found fluoroquinolone residues in rivers near both urban and rural areas, with concentrations high enough to select for resistance in aquatic bacteria. Tackling the informal market alone will not solve the broader resistance crisis, but it is a critical piece of the puzzle.

None of these measures is a silver bullet. Resistance is a biological inevitability, and the genie of informal antibiotic sales will not be easily put back in the bottle. But with coordinated action, it may be possible to preserve the effectiveness of the antibiotics we still have—and prevent the return of a time when a simple urinary tract infection could become a life-threatening event.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment of infections.